Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Structural Genomics Consortium (SGC) is a key member of a new EUbOPEN consortium which has been awarded funding from the Innovative Medicines Initiative to develop openly available chemical tools for understanding human biology.

None

The Oxford Structural Genomics Consortium (SGC) is a key member of a new consortium, “Enabling and Unlocking biology in the Open” (EUbOPEN), which has been awarded an Innovative Medicines Initiative grant worth over 66 million Euros. The project will last five years.

The EUbOPEN project builds on the efforts of the successful ULTRA-DD consortium previously led by the University of Oxford, and will be led by Goethe University Frankfurt, and the pharmaceutical company Boehringer Ingelheim. The consortium consists of 22 partners from academia and industry that will work together to develop high quality chemical tools that can be used to investigate the biology of disease and discover new targets for drug discovery. In keeping with the SGC commitment to open science, the project outputs will be made openly available to the research community, without restriction, including chemogenomic library sets, chemical probes, assay protocols and associated research data.

The research at the University of Oxford will be directed by Professor Chas Bountra, the Chief Scientific Officer of SGC Oxford and the University of Oxford’s Pro Vice-chancellor for innovation, and Dr Jon Elkins, Principal Investigator at SGC Oxford.

Read more on the EUbOPEN website

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.